Recent research has suggested that RIPK3 promotes anti-cancer immune response by regulating natural killer T cells, as RIPK3(−/−) mice show reduced natural killer T cell responses to metastatic tumor cells (133). This evidence concerns the gene RIPK3 and neoplasm.